Close Menu

NEW YORK – OpGen said Wednesday after the close of the market that its second quarter revenues grew 28 percent year over year as the company continues to await US Food and Drug Administration clearance for its antimicrobial resistance test.

For the three months ended June 30, the Gaithersburg, Maryland-based firm reported revenues of $1.0 million compared to $788,901 a year ago, on par with the average analyst estimate of $1.0 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.